Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bausch HealthLTS:0QYW 65 EV-to-FCF is 16.28 as of Aug. 08, 2026, which is 28% below its 10-year median of 22.70. GuruFocus rates LTS:0QYW with a GF Score™ of 65/100 and a GF Value™ of CHF157.98. The stock has 3 warning signs investors should review. Among 569 Drug Manufacturers companies, Bausch Health ranks better than 63.09% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bausch Health's Enterprise Value is CHF18,075 Mil.
Bausch Health's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was CHF1,110 Mil. Therefore, Bausch Health's EV-to-FCF for today is 16.28.
The historical rank and industry rank for Bausch Health's EV-to-FCF or its related term are showing as below:
LTS:0QYW'
s EV-to-FCF Range Over the Past 10 Years
Min: -37.05 Med: 22.7 Max: 47.72
Current: 16.02
During the past 13 years, the highest EV-to-FCF of Bausch Health was 47.72. The lowest was -37.05. And the median was 22.70.
LTS:0QYW's EV-to-FCF is ranked better than 63.09% of 569
companies
in the Drug Manufacturers industry
Industry Median: 21.6
vs LTS:0QYW: 16.02
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bausch Health's PE Ratio (TTM) for today is calculated as:
Bausch Health's share price for today is CHF122.93991.
Bausch Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-2.320.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bausch Health EV-to-FCF Related Terms
Bausch Health EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Bausch Health's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch Health EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bausch Health's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Bausch Health's EV-to-FCF falls into.
Bausch Health's current Enterprise Value is CHF18,075 Mil.
Bausch Health's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF1,110 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch Health (LTS:0QYW) has a EV-to-FCF of 16.28 as of Aug. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bausch Health and its competitors. This is 28% below median its historical median of 22.70. According to the industry distribution chart, Bausch Health ranks #210 out of 569 companies in the Drug Manufacturers industry, placing it in the top 36.9%.
Is Bausch Health's EV-to-FCF too high?
Bausch Health's current EV-to-FCF of 16.28 is 28% below median its 10-year median of 22.70. The Drug Manufacturers industry median EV-to-FCF is 21.60. Bausch Health's value of 16.28 is 24.6% below this industry median. Based on the distribution chart, Bausch Health ranks #210 out of 569 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bausch Health has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Bausch Health's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bausch Health ranks #210 out of 569 companies for EV-to-FCF. This puts Bausch Health in the upper half of its industry. The industry median EV-to-FCF is 21.60. Bausch Health's value of 16.28 is 24.6% below this benchmark. While the company's 10-year median is 22.70 vs. the industry median of 21.60, Bausch Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.60, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bausch Health's current EV-to-FCF of 16.28 is 24.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bausch Health and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch Health's current EV-to-FCF is 16.28, which is 28% below median its own 10-year median of 22.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch Health stock overvalued right now?
Bausch Health (LTS:0QYW) has a current EV-to-FCF of 16.28. The stock's GF Value™ is CHF157.98, compared to a current price of CHF122.94 — trading 22.2% below its estimated fair value. The current EV-to-FCF is 16.28, which is 28% below median its 10-year median of 22.70 and 24.6% below the Drug Manufacturers industry median of 21.60. Bausch Health's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Bausch Health (LTS:0QYW), the current EV-to-FCF is 16.28 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch Health (LTS:0QYW) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued.
The current stock price of CHF122.94 is trading 22.2% below its estimated GF Value™ of CHF157.98.
Key valuation signals for LTS:0QYW:
EV-to-FCF: 16.28 (28% below median its 10-year median of 22.70)
GF Value™: CHF157.98 vs. price of CHF122.94 (22.2% below fair value)
Industry Position: 24.6% below the Drug Manufacturers median (#210 of 569)
No single metric tells the full story. See the LTS:0QYW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
65GF Score
Get the complete analysis for LTS:0QYW
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QYW has been successfully added to your 
